MERCK MK-5475 in PAH, Phase 23 A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension
- Sahay, Sandeep (PI)
- Safdar, Zeenat (Key Personnel)
Project: Clinical Trial